Company record · ALLO
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. disclosed a change in its chief financial officer, effective November 6, 2026. Until then the filing lists Geoffrey Parker in the role. See the filing record.
Tracked changes
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.